Every 424B that Predictive Oncology Inc. (POAI) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 424B covers the supplement that carries the terms of a priced offering, so if you follow POAI and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full POAI filings page.
Registers up to $100,000,000 of Common Stock under an at-the-market sales agreement. This prospectus supplement amends the ATM Prospectus to increase the aggregate amount available for sale under the Sales Agreement with H.C. Wainwright & Co., LLC to $100.0 million, including shares previously sold.
The supplement states the company has sold 1,334,907 shares for approximately $17.0 million under the Sales Agreement and previously sold 1,203,544 shares for aggregate gross proceeds of approximately $12.7 million (adjusted for a one-for-fifteen reverse split). As of May 15, 2026, the public float is reported at $90.0 million based on 10,282,258 shares held by non-affiliates. The filing also discloses ownership of approximately 6.209 billion ATH tokens valued at $42.1 million as of May 14, 2026, and a last reported Nasdaq sale price of $5.60 per share on May 14, 2026.
Predictive Oncology Inc. (POAI) is registering the resale by existing investors of up to 14,903,393 shares of common stock issuable upon exercise of pre-funded warrants from a prior private Crypto PIPE financing. The company itself is not selling any shares in this prospectus, and the selling stockholders will receive all proceeds from any share sales. POAI will receive only the nominal cash proceeds if holders choose to exercise their warrants.
The filing details POAI’s shift toward a digital asset treasury strategy centered on Aethir (ATH) tokens alongside its AI-driven oncology drug discovery business. As of November 25, 2025, POAI held about 5.9 billion ATH with an indicated market value of approximately $97.4 million, highlighting significant exposure to ATH price movements and related regulatory and operational risks.
Predictive Oncology Inc. (POAI) has registered 5,970,181 shares of common stock for potential resale by existing investors. The shares consist of 2,547,789 PIPE Shares issued in August and September 2025 and 3,422,392 shares underlying various warrants, including Cash PIPE Warrants, placement agent warrants and advisor warrants. The company itself is not selling any shares in this prospectus and will only receive cash if holders choose to exercise their warrants.
The filing explains that Predictive Oncology is building an AI-driven oncology drug discovery business while also operating a digital asset treasury focused on Aethir tokens (ATH). As of November 21, 2025, the company held about 5.6 billion ATH, valued at approximately $90.2 million at $0.0161 per token, and plans to expand this position through additional purchases and staking. The prospectus highlights significant risks tied to ATH price volatility, regulatory uncertainty for digital assets, and the concentration of a large portion of the balance sheet in a single token.
Predictive Oncology (POAI) filed a prospectus supplement for an at-the-market offering of up to $18,330,000 of common stock under its agreement with H.C. Wainwright, subject to General Instruction I.B.6 limits.
Over the last 12 months, the company sold 139,680 shares for aggregate gross proceeds of approximately $1,872,333 through the ATM. As calculated within 60 days of this supplement, public float was $62,257,699, based on 3,458,934 non‑affiliate shares at $17.9991. The company noted $2,417,337 of securities sold pursuant to I.B.6 in the same period. If public float rises above $75.0 million, the I.B.6 cap would no longer apply; additional capacity would be reflected in a future supplement.
As of October 28, 2025, the company held approximately 5.49 billion Aethir tokens valued at about $159.2 million based on a $0.0290 price.